Printed From:

About the Synvisc® Family


EFFICACY

The SYNVISC® family of viscosupplements provide up to 6 months of OA knee pain relief with a single course of
treatment.1-4


SCIENCE

SYNVISC®/Synvisc-One® delivers a nonsystemic solution for your OA knee pain relief needs.1,2

In a study of patients treated with SYNVISC, most patients who were taking concomitant therapy for OA knee pain reported less or discontinued use of analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids.3

  • Local treatment-related adverse events (AEs) were reported in 4.2% of patients and 2.4% of injections3

“[Viscosupplementation] is an important conservative treatment modality in the care and treatment of patients with OA of the knee.4

— Bert JM, Waddell DD. Ther Adv Musculoskelet Dis. 2010;2(3):127-132.


EVIDENCE

In separate, head-to-head clinical trials, only the SYNVISC family of viscosupplements demonstrated superior OA knee pain relief versus all of the following:

ICS = intra-articular corticosteroid

View SYNVISC vs noncrosslinked sodium hyaluronate study details.

View additional head-to-head study details.


SAFETY

The SYNVISC family of viscosupplements has an established safety profile.5,6,10


EXPERIENCE

SYNVISC and Synvisc-One have been included in more than 300 publications and used to treat more than 15 million knees worldwide.11


References

  1. SYNVISC (hylan G-F 20) [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  2. Synvisc-One (hylan G-F 20) [prescribing information]. Cambridge, MA: Genzyme Corporation; 2014.
  3. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269.
  4. Bert JM, Waddell DD. Viscosupplementation with hylan G-F 20 in patients with osteoarthrosis of the knee. Ther Adv Musculoskelet Dis. 2010;2(3):127-132.
  5. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410-423.
  6. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69(1):113-119.
  7. Caborn D, Rush J, Lanzer W, Parenti D, Murray C; Synvisc 901 Study Group. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333-343.
  8. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995;3(4):213-225.
  9. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee—a prospective randomized clinical trial. Knee. 2008;15(4):318-324.
  10. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269.
  11. IMS sales data, 2017

MySynviscONETM

See how you’ll get the convenience of benefit verification, e-ordering
and online inventory management.

Watch Video ›

Order Synvisc-One® and SYNVISC®

Learn about the different ordering options and how to get next-day delivery with your MySynviscONE™ account.

Order now ›

Resources for
Your Patients

Share these tools to help patients get the most out of their treatment.

Browse Resources ›